Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1

Status

Completed 1250Recruiting 441Unknown 352Terminated 343Active not recruiting 321Not yet recruiting 126Withdrawn 96Enrolling by invitation 5Suspended 4

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 3NET 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Cisplatin 9Standard of Care 6Educational Status 6Nivolumab 5Interviews as Topic 5Carboplatin 5Radiotherapy 4Paclitaxel 4Oxaliplatin 4Dexamethasone 4pembrolizumab 3camrelizumab 3Practice Guidelines as Topic 3Patient Navigation 3Methods 3Magnetic Resonance Spectroscopy 3Magnetic Resonance Imaging 3Lenalidomide 3Fluorouracil 3Fluorodeoxyglucose F18 3Exercise 3Early Intervention, Educational 3Drug Therapy 3Cytarabine 3130-nm albumin-bound paclitaxel 3venetoclax 2toripalimab 2tislelizumab 2sacituzumab govitecan 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Carboplatin × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06755515 2025-01-01

A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Shandong New Time Pharmaceutical Co., LTD

Phase 2/3 Enrolling by invitation
510 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06303583 2024-03-12

CRIS

Zhejiang Cancer Hospital

Phase 1/2 Enrolling by invitation
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡